The studies that will be described in Chapter 2 to 8, and which resulted in this thesis, aim to evaluate the effectiveness and safety of new HIV treatment strategies with INSTIs, especially DTG, in HIV-1 infected individuals. Furthermore, several aspects of cART-toxicity with dual NRTI backbones in combination with an INSTI, PI, or NNRTI are evaluated. The ultimate goal is a more individualized and patient-centered therapy by balancing virological and immunological efficacy with reduction of the risk of adverse events.

This thesis focuses on three issues.
Part 1 focuses on the effects of a switch from triple cART to DTG as maintenance monotherapy.
In part 2 the safety of initiating INSTI-containing cART in HIV late presenters with compromised immunity on the risk of IRIS is discussed.
Part 3 concentrates on aspects regarding safety of the NRTI backbone in INSTI, PI, or NNRTI containing cART and possibilities to further individualize HIV treatment.

HIV, antiretroviral therapy, integrase strand transfer inhibitors
A. Verbon (Annelies) , B.J.A. Rijnders (Bart) , C. Rokx (Casper)
Erasmus University Rotterdam
Department of Medical Microbiology and Infectious Diseases

Wijting, I.E.A. (2019, January 8). HIV Treatment Strategies – The role of integrase strand transfer inhibitors. Erasmus University Rotterdam. Retrieved from